BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19 The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Feb 4, 2020
Finance

Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO. Founded in...
BioCentury | Oct 30, 2019
Politics & Policy

Cuccinelli accepts responsibility for decision to deport patients

...for Patients” ). Bueso traveled to the U.S. to participate in a trial of Naglazyme galsulfase...
BioCentury | Sep 20, 2019
Politics & Policy

Administration reverses policy decision on deferred action for patients

...the U.S. from Guatemala as a child and participated in the original trial of Naglazyme galsulfase...
BioCentury | Sep 11, 2019
Politics & Policy

Few answers from hearing on medical deferred action

...the U.S. from Guatemala as a child and participated in the original trial of Naglazyme galsulfase...
BioCentury | Sep 4, 2019
Politics & Policy

U.S. reconsidering deportation orders for patients receiving medical treatment

...Jean-Jacques Bienaimé, chairman and CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), told BioCentury. BioMarin manufacturers Naglazyme galsulfase...
BioCentury | Mar 29, 2019
Clinical News

Orchard planning MAA for leukodystrophy stem cell gene therapy

Orchard plans to submit an MAA to EMA in 2020 for OTL-200 to treat metachromatic leukodystrophy after reporting that the therapy met a co-primary endpoint of improving motor function at two years following treatment in...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

...annual WAC of about $217,880, not counting any discounts. The WAC for the biotech’s Naglazyme galsulfase...
...of rare disease company BioMarin during 1998-2009, he led development and commercialization of Aldurazyme and Naglazyme...
Items per page:
1 - 10 of 142